

SATURDAY, NOVEMBER 1, 2025

Thoracic Malignancies: A Review of the Latest Evidence

The rapid evolution of information surrounding the management of thoracic malignancies presents ongoing challenges for physicians tasked with selecting the most appropriate treatment strategies. To address this, Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education (CME) are offering a comprehensive course focused on the latest advances in the detection, imaging, diagnosis, staging, treatment, and research of non-small cell lung cancer (NSCLC).

This full-day CME event features experts from Fox Chase/Temple Health, Massachusetts General Hospital/Harvard Medical School, Penn Medicine, Jefferson Health, Cooper University Health Care, Montefiore Einstein Comprehensive Cancer Center, Alliance Cancer Specialists, and Virginia Cancer Specialists. The course is designed to provide practical, up-to-date insights for anyone involved in the care of lung cancer patients or seeking a current overview of the field.

Registration: FoxChase.org/CME

DATE

Saturday, November 1, 2025

7:30 AM Check-in & Breakfast

8:00 AM-3:30 PM CME Program



LOCATION

Philadelphia Marriott Old City
One Dock Street, Philadelphia, PA 19106

INQUIRIES

Lucía Tono, PhD, MEd

Lucia.Tono-Ramirez@tuhs.temple.edu

Educational Objectives

- Identify MET IHC-positive tumors and select appropriate treatment strategies.
- Select patients with early-stage lung cancer who are appropriate candidates for neoadjuvant therapy.
- Determine the optimal frontline treatment for patients with advanced EGFR-mutated NSCLC.

Keynote Speaker:

FRONTLINE METASTATIC



Zosia Piotrowska, MD, MHS

Associate Professor of Medicine,
Harvard Medical School

Associate Physician,
Medicine-Hematology and Medical Oncology,
Massachusetts General Hospital

Intended Audience:

This course is appropriate for primary care and family medicine physicians; medical, surgical, and radiation oncologists; thoracic and general surgeons; pulmonologists; pathologists; radiologists; fellows/residents/students; nurses; physician assistants; advanced practice providers; and researchers involved in the management of patients with lung cancer and thoracic malignancies.

Program Director:



Hossein Borghaei, DO, MS

Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Co-Director, Immune Monitoring Facility
Gloria and Edmund M. Dunn Chair in Thoracic Oncology

Planning Advisor



Michael Seidman, MD

Professor, Department of Hematology/Oncology
Fox Chase Cancer Center



**Fox Chase
Cancer Center**
Temple Health

Thoracic Malignancies: A Review of the Latest Evidence

Check-in, Breakfast, & Exhibits Open (7:30 AM–8 AM)

Welcome & Opening Remarks (8 AM–8:10 AM)

Hossein Borghaei, DO, MS, *Fox Chase Cancer Center*

Session 1: EGFR (8:10 AM–9:10 AM)

- **KEYNOTE SPEAKER: Frontline Metastatic**
Zosia Piotrowska, MD, MHS, *Massachusetts General Hospital*
- **Second Line and Beyond Metastatic**
Nick Bodor, MD, PhD, MPH, *Fox Chase Cancer Center*
- **Adjuvant and Neoadjuvant**
Sukhmani Padda, MD, *Fox Chase Cancer Center*
- **Management of Toxicities**
Zosia Piotrowska, MD, MHS, *Massachusetts General Hospital*
- **Panel Discussion and Case Studies**

Session 2: HER2 (9:10 AM–9:50 AM)

- **Brain Mets**
Stephanie E. Weiss, MD, FASTRO, *Fox Chase Cancer Center*
- **ADC**
Parth Desai, MBBS, MD, *Fox Chase Cancer Center*
- **TKIs**
Lova Sun, MD, MSCE, *Penn Medicine's Abramson Cancer Center*
- **Panel Discussion and Case Studies**

Break (9:50 am–10:05 am)

Session 3: Locally Advanced (10:05 AM–10:55 AM)

- **Chemo-RT-IO Studies (No Driver)**
Martin J. Edelman, MD, FACP, *Fox Chase Cancer Center*
- **New Paradigm: How to Move Forward**
Sameera Kumar, MD, *Fox Chase Cancer Center*
- **Locally Advanced Disease (Driver Mutation-Positive Studies)**
Deric Savior, MD, *Alliance Cancer Specialists*
- **Panel Discussion and Case Studies**
Moderator: John C. Ruckdeschal, MD, FACP, FCCP,
Fox Chase Cancer Center

Session 4: Early Stage Disease (10:55 AM–11:50 AM)

- **Adjuvant and Neoadjuvant: Updated Data**
Corey Langer, MD, *Penn Medicine's Abramson Cancer Center*
- **Adjuvant and Neoadjuvant in Driver-Positive Disease**
Nick Bodor, MD, PhD, MPH, *Fox Chase Cancer Center*
- **Surgical Perspectives**
Stacey Su, MD, FACS, *Fox Chase Cancer Center*
- **Panel Discussion and Case Studies**

Lunch/Exhibitors (11:50 AM–12:50 PM)

Session 5: Metastatic Disease (12:50 PM–2:00 PM)

- **Frontline Studies Update**
Balazs Halmos, MD, MS, *Montefiore Einstein Comprehensive Cancer Center*
- **Post-IO Studies**
Hossein Borghaei, DO, MS, *Fox Chase Cancer Center*
- **ADCs and Bispecific Antibodies**
Neel Belani, MD, *Virginia Cancer Specialists*
- **Management of Toxicities**
Carolyn Zawislak, PA-C, *Fox Chase Cancer Center*
- **Consolidative Radiation Therapy**
Sameera Kumar, MD, *Fox Chase Cancer Center*
- **Oligo Met, Oligo Progressive, Oligo Whatever**
Randi Cohen, MD, MS, *Fox Chase Cancer Center*
- **Panel Discussion and Case Studies**

Session 6: Small Cell (2:00 PM–2:40 PM)

- **Frontline ES-SCLC**
Veli Bakalov, MD, *Cooper University Health Care*
- **Second-Line ES-SCLC**
Parth Desai, MBBS, MD, *Fox Chase Cancer Center*
- **LS-SCLC**
Martin J. Edelman, MD, FACP, *Fox Chase Cancer Center*
- **Panel Discussion and Case Studies**

Session 7: Tumor Board (2:40 PM–3:20 PM)

John C. Ruckdeschal, MD, *Fox Chase Cancer Center*
Jason A. Damsker, MD, FACP, *Fox Chase Cancer Center*
Leah Holben, MD, *Fox Chase Cancer Center*
Michael Seidman, MD, *Fox Chase Cancer Center*
Stacey Su, MD, FACS, *Fox Chase Cancer Center*
Ahmad Danish, MD, *Fox Chase Cancer Center*

Closing Remarks (3:20 PM–3:30 PM)

ACCREDITATION STATEMENT: The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians. Fox Chase Cancer Center is approved as a provider of nursing continuing professional development by the Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

DESIGNATION STATEMENT: The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of **6 AMA PRA Category 1 Credits™**. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity. Fox Chase Cancer Center designates this live activity for a maximum of **6 Hour(s) NCPD (ANCC Contact Hours)**. Participants should claim only the credit commensurate with the extent of their participation in the activity.